<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27066571</article-id>
<article-id pub-id-type="pmc">4811382</article-id>
<article-id pub-id-type="publisher-id">NG2015000646</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000034</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mutation in the sixth immunoglobulin domain of <italic>L1CAM</italic> is associated with migrational brain anomalies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shieh</surname>
<given-names>Christine</given-names>
</name>
<degrees>BS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moser</surname>
<given-names>Franklin</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graham</surname>
<given-names>John M.</given-names>
<suffix>Jr</suffix>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Guest Editor, European Journal of Medical Genetics, Special Issue on Genetics of Common Malformations, European Journal of Medical Genetics, January 2014. Editorial Board Member: Clinical Pediatrics, 1983-present. Editorial Board Member, American Journal of Medical Genetics, 1995-2001; 2009-present Editorial Board Member, Congenital Anomalies (Japan), 2000-present Editorial Board Member, European Journal of Medical Genetics, 2004-present. Editorial Board Member, Global Pediatric Health, 2014-present. International Advisory Board for Indian Academy of Medical Genetics, 2012-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>Graham J.M. Jr., Smith's Recognizable Patterns of Human Deformation, 3rd Edition, Philadelphia, Elsevier-W.B. Saunders Co., Philadelphia, PA, 2007.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>Zoloft Product Liability Litigation (Pfizer, Inc) 2013-present Depakote Product Liability (Abbott) 2014-present Murphy v. NXP Semiconductors (Paternally derived NKX2.2 disruption) Organic Solvent Exposure (Defense) Bustamante v. Children?s Hospital of Los Angeles (22q11.2 del-IAA) (Defense) 2014 Bartlett, Wolf v du Pont Co. (Perfluorooctanoic acid in water supply) (Defense) 2014- present Numkena v Motorola (Cerebral Palsy) (Organic Solvents) (Defense) 2015 Kirk and Goode v Varco (Fetal Akinesia: Autism and Asthma)(Organic Solvents) Defense 2014-present</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Watiker</surname>
<given-names>Valerie</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Pierson</surname>
<given-names>Tyler Mark</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the David Geffen School of Medicine at UCLA (C.S.), Los Angeles, CA; and Division of Clinical Neuroradiology and Interventional Neuroradiology (F.M.), Division of Clinical Genetics and Dysmorphology (J.M.G.), Department of Pediatrics (J.M.G., V.W.), Department of Pediatrics and Neurology (T.M.P.), and Board of Governors Regenerative Medicine Institute (T.M.P.), Cedars-Sinai Medical Center, Los Angeles, CA.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Pierson: <email>tyler.pierson@cshs.org</email></corresp>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000034">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge was paid by the authors.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>11</month>
<year>2015</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
<volume>1</volume>
<issue>4</issue>
<elocation-id>e34</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>7</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>9</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© 2015 American Academy of Neurology</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2015000646.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To describe the phenotype of a patient with classical features of X-linked L1 syndrome associated with novel brain malformations.</p>
</sec>
<sec>
<title>Methods:</title>
<p>Diagnostic analysis included physical and dysmorphology examinations, MRI of the brain, and exome sequencing of the family trio.</p>
</sec>
<sec>
<title>Results:</title>
<p>We report a 2.5-year-old boy with developmental delay, dysmorphic facies, and adducted thumbs. MRI of the brain showed a truncated corpus callosum and periventricular heterotopias associated with polymicrogyria (PMG). Variant segregation analysis with exome sequencing discovered a novel maternally derived hemizygous variant in exon 14 of the <italic>L1CAM</italic> gene (c.1759 G&gt;C; p.G587R).</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>This novel <italic>L1CAM</italic> mutation was located in the protein's sixth immunoglobin domain and involved glycine-587, a key residue in the structure of L1CAM because of its interactions with lysine-606, which indicates that any mutation at this site would likely affect the secondary structure and function of the protein. The replacement of the small nonpolar glycine residue with a large basic arginine would have an even more dramatic result. The presentation of periventricular nodular heterotopias with overlying PMG is very uncommon, and its association with L1CAM may provide insight into other similar cases. Furthermore, this presentation indicates the important role that L1CAM plays in neuronal migration and brain development and extends the phenotype associated with L1CAM-associated disorders.</p>
</sec>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>The L1 family of adhesion molecules is involved in several processes during the development of the brain. These events occur through L1CAM's interactions with various proteins and involve myelination, neuronal outgrowth, axon fasciculation, and neuron migration.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Mutations in <italic>L1CAM</italic> have previously been associated with 4 X-linked neurologic conditions, collectively known as L1 syndrome: X-linked hydrocephalus, MASA syndrome (mental retardation, aphasia, shuffling gait, and adducted thumbs), spastic paraplegia type 1 (SPG-1), and X-linked agenesis of the corpus callosum.<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref></sup></p>
<p>L1CAM consists of a conserved cytoplasmic, 5 fibronectin type III, and 6 extracellular immunoglobulin (Ig1–6) domains.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> The Ig1–6 and the second fibronectin domain are responsible for homophilic binding that triggers neurite outgrowth, while heterophilic binding involves the neurocan protein or the integrins interacting with other L1CAM domains.<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup> Of note, the sixth Ig domain promotes neurite outgrowth through both homophilic binding and heterophilic binding to integrins.<sup><xref ref-type="bibr" rid="R5">5</xref></sup></p>
<p>More than 200 <italic>L1CAM</italic> mutations have been reported, with a range of phenotypes.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Patients were classified as having a “severe” phenotype if they had macrocephaly that required shunting or died before 2 years of age; all others were classified as having a “mild” phenotype.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> Patients with cytoplasmic domain mutations often presented with a mild phenotype, while extracellular domain mutations were more severe. Further analysis of missense mutations noted that variants involving the surface of the extracellular domain were milder than those affecting its core.<sup><xref ref-type="bibr" rid="R3">3</xref></sup></p>
<p>We report a 2.5-year-old boy with a novel <italic>L1CAM</italic> mutation. Classical features of L1 syndrome were present, including callosal hypoplasia, intellectual disability, adducted thumbs, and SPG.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup> Unique to this patient was the presence of periventricular nodular heterotopias (PNHs) associated with overlying polymicrogyria (PMG).</p>
<sec id="s1" sec-type="methods">
<title>METHODS</title>
<sec id="s1-1">
<title>Standard protocol approvals, registrations, and patient consents.</title>
<p>Research protocols were approved through the institutional review board, and the family gave informed consent (CSMC IRB protocol Pro00037131).</p>
</sec>
<sec id="s1-2">
<title>Patient.</title>
<p>The proband was a 2.5-year-old boy who presented with dysmorphic features, motor disabilities, and cognitive delay. He was the second child of a nonconsanguineous couple of Thai descent. He had an unaffected sister and no family history of neurologic disease.</p>
<p>At birth, the child was described as having several dysmorphic features, including a wide nasal bridge, hypertelorism, sparse eyebrows/eyelashes, microstomia, retrognathia, and posteriorly rotated ears (<xref ref-type="fig" rid="F1">figure 1A</xref>). He had a high palate and a bifid uvula. He had arachnodactyly, overlapping digits, and adducted thumbs. His first and second toes were widely spaced bilaterally, and there was partial syndactyly between the second and third toes on the left foot. His birth weight was 3,319 g, length was 48 cm, and head circumference was 33 cm, all within normal limits. He exhibited poor feeding and required gastrostomy tube placement.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Photographs of the patient</title>
<p>Patient (A) as an infant and (B) at 2.5 years of age. Note the microcephaly, sparse lashes, broad nasal bridge, and small-appearing mouth with downturned corners. (C) Profile view at 2.5 years of age with posteriorly rotated ears and retrognathia.</p>
</caption>
<graphic xlink:href="NG2015000646FF1"></graphic>
</fig>
<p>On examination, the child was awake and alert. He did not speak or follow commands. He had limited receptive language. Head circumference and length were below the 5th percentile. He had developed bushy eyebrows, low posterior hairline, and thick hair with frontal upsweep and disorganized growth pattern (<xref ref-type="fig" rid="F1">figure 1B</xref>). He had a mild apparent hypertelorism, wide nasal bridge, a small-appearing mouth with downturned corners and retrognathia, high palate, and bifid uvula (<xref ref-type="fig" rid="F1">figure 1B</xref>). He had low-set posteriorly rotated ears with an abnormal helix (<xref ref-type="fig" rid="F1">figure 1C</xref>). Visual tracking was decreased. He had adducted thumbs and SPG. Strength was mildly and diffusely decreased. His reflexes were brisk. His ankles were dorsiflexed with talipes calcaneovalgus deformities.</p>
<p>MRI of the brain at 1 year of age revealed a truncated corpus callosum with incomplete formation of the genu and rostrum anteriorly and the splenium posteriorly (<xref ref-type="fig" rid="F2">figure 2A</xref>). There was deformation of the lateral ventricles with larger anterior horns. Bilateral PMG was present and associated with PNHs (<xref ref-type="fig" rid="F2">figure 2B</xref>). White matter signal abnormalities were present, with reduced volume consistent with dysmyelination (<xref ref-type="fig" rid="F2">figure 2C</xref>). Both the pons and medulla were small and not fully developed (<xref ref-type="fig" rid="F2">figure 2A</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Brain MRI at 1 year of age</title>
<p>(A) Sagittal T1 imaging revealed truncation of the rostrum, genu, and splenium of the corpus callosum. (B) Axial T1 imaging showed periventricular nodular heterotopias (black arrows), polymicrogyria, and enlarged lateral ventricles that are widely separated and abnormal in shape. (C) Coronal axial fluid-attenuated inversion recovery imaging showed hyperintense white matter (white arrows) with reduced volume, consistent with dysmyelination.</p>
</caption>
<graphic xlink:href="NG2015000646FF2"></graphic>
</fig>
</sec>
<sec id="s1-3">
<title>Genetic evaluation.</title>
<p>Genomic DNA was extracted from blood, and exome sequencing was performed as per previous protocols (GeneDx, Gaithersburg, MD).<sup><xref ref-type="bibr" rid="R6">6</xref></sup></p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<p>Exome sequencing identified a novel maternally derived missense mutation (c.1759 G&gt;C; p.Gly587Arg) in exon 14 of the <italic>L1CAM</italic> gene (NM_000425.3). This variant was not observed in approximately 6,500 individuals in the NHLBI Exome Sequencing Project.</p>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>Our proband was hemizygous for a missense mutation in the sixth Ig domain of the <italic>L1CAM</italic> gene. This mutation involves the substitution of a nonpolar glycine residue with a larger basic arginine residue. Previously, glycine-587 was identified as a key residue in the structure of L1CAM because of its interactions with lysine-606, which indicates that any mutation at this site would likely affect the secondary structure and function of the protein (<xref ref-type="fig" rid="F3">figure 3A</xref>).<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Furthermore, glycine-587 residue is conserved across mammalian species (<xref ref-type="fig" rid="F3">figure 3B</xref>), and neither this variant nor any other variant has been previously reported to affect this residue. Consistent with these findings, the child had several features associated with L1CAM disorders, in addition to some unique migrational anomalies of his brain. Other nearby mutations (p.Y589H, p.A593P, p.D598N) that were previously associated with L1 syndrome (corpus callosum hypoplasia, retardation, adducted thumbs, and spasticity) provide additional evidence that this substitution is responsible for his phenotype.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Furthermore, investigations in C57BL/6 mice with deletion of L1CAM's sixth Ig domain (L1-6D mice) resulted in a typical L1 phenotype consisting of hydrocephalus and embryonic lethality.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> This phenotype was likely the result of loss of L1–L1 homophilic binding that is important for axon fasciculation, extension, and guidance, as well as loss of heterophilic integrin binding that triggers signaling pathways involved in cell migration.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup></p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Diagram of L1CAM extracellular domains and glycine-587 conservation</title>
<p>(A) Schematic of the L1CAM protein extracellular domains with glycine-587 (G*) and lysine-606 (L) residues highlighted.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R4">4</xref></sup> Fibronectin type III domains = FN in square; immunoglobulin domain = Ig in circle; RGD motif = RGD in box. (B) Glycine-587 (*) is conserved across several mammalian species.</p>
</caption>
<graphic xlink:href="NG2015000646FF3"></graphic>
</fig>
<p>PNHs are defined as heterotopic nodules of disorganized neurons along lateral ventricles of the brain. It has been hypothesized that these abnormalities are caused by impaired departure of neurons from the ventricular zone (VZ). In murine neocortex, shRNA knockdown of L1CAM showed impaired migration of neurons from the VZ to the intermediate zone (IZ) and the cortical plate.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Altered distribution of the leading processes of neurons led to aberrant locomotion.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> A similar defect was observed in slice culture experiments of neuronal L1CAM knockdown (L1-KD) mice, in which L1-KD neurons had decreased locomotion in the IZ and longer processes when translocating through the primitive cortical zone.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> These defects were likely caused by impaired homophilic binding and inadequate activation of MAPK, resulting in slowed migration. In addition, it has been reported that integrins such as α3β1 and α5β1 modulate the interaction between the leading processes of the neurons and substrate as they migrate through the cortical zone.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> It is likely that our proband's mutation and its proximity to a nearby RGD motif in Ig6 disrupted both homophilic and integrin binding, resulting in impaired cell signaling and causing migrational abnormalities.</p>
<p>Our patient's presentation with PNHs associated with PMG appears to be novel in L1CAM-associated disorders. Several patients with an X-linked inheritance pattern of familial hydrocephalus thought to be due to <italic>L1CAM</italic> mutations were also noted to have PMG.<sup><xref ref-type="bibr" rid="R11">11</xref></sup> Unfortunately, a genetic diagnosis was never confirmed.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> More interesting is that PNHs with overlying frontal-perisylvian PMG have been previously described in only a handful of patients,<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup> and nearly all of the individuals with this subtype were males with limb abnormalities.<sup><xref ref-type="bibr" rid="R12">12</xref></sup> Unfortunately, the genetic factors causing this combination also have yet to be identified. Further investigations of those cases with an emphasis on <italic>L1CAM</italic> may be appropriate.</p>
<p>We have described a case of an <italic>L1CAM</italic>-associated disorder caused by a hemizygous missense mutation in its sixth Ig domain. This mutation likely disrupted the secondary structure of L1CAM, resulting in abnormal homophilic and integrin binding and leading to the common symptoms of L1 syndrome along with a novel presentation of specific migrational abnormalities.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>The authors are grateful to the patient and the parents for their cooperation, and they thank Kelli DeJohn and Shantel Brown for excellent administrative assistance and Barrington Burnett for critical analysis. T.M.P. was supported by Cedars-Sinai Medical Center institutional funding and the Diana and Steve Marienhoff Fashion Industries Guild Endowed Fellowship in Pediatric Neuromuscular Diseases.</p>
</ack>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">Christine Shieh: study concept and design and writing of manuscript. Franklin Moser: acquisition of data, analysis, and interpretation. John Graham: acquisition of data, analysis, and interpretation. Valerie Watiker: acquisition of data; critical revision of the manuscript for important intellectual content. Tyler Pierson: study concept and design, writing of manuscript; study supervision; critical revision of the manuscript for important intellectual content.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">No targeted funding reported.</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">Christine Shieh and Franklin Moser report no disclosures. John Graham has served on the editorial boards of the <italic>European Journal of Medical Genetics</italic>, <italic>Clinical Pediatrics</italic>, the <italic>American Journal of Medical Genetics</italic>, <italic>Congenital Anomalies</italic>, <italic>Global Pediatric Health</italic>, and the International Advisory Board for <funding-source>Indian Academy of Medical Genetics</funding-source>; has received royalties for <italic>Smith's Recognizable Patterns of Human Deformation</italic>; and has had involvement in the following legal proceedings: Zoloft Product Liability Litigation (Pfizer, Inc.), Depakote Product Liability (Abbott), Murphy v. NXP Semiconductors (Paternally derived NKX2.2 disruption) Organic Solvent Exposure, Bustamante v. Children's Hospital of Los Angeles, Bartlett, Wolf v du Pont Co. (Perfluorooctanoic acid in water supply), Numkena v Motorola (Cerebral Palsy) (Organic Solvents), and Kirk and Goode v Varco (Fetal Akinesia: Autism and Asthma) (Organic Solvents). Valerie Watiker and Tyler Pierson report no disclosures. Go to <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000034">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">Ig</term>
<def>
<p>immunoglobulin</p>
</def>
</def-item>
<def-item>
<term id="G2">IZ</term>
<def>
<p>intermediate zone</p>
</def>
</def-item>
<def-item>
<term id="G3">PMG</term>
<def>
<p>polymicrogyria</p>
</def>
</def-item>
<def-item>
<term id="G4">PNH</term>
<def>
<p>periventricular nodular heterotopia</p>
</def>
</def-item>
<def-item>
<term id="G5">SPG-1</term>
<def>
<p>spastic paraplegia type 1</p>
</def>
</def-item>
<def-item>
<term id="G6">VZ</term>
<def>
<p>ventricular zone</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hortsch</surname><given-names>M</given-names></name></person-group>
<article-title>The L1 family of neural cell adhesion molecules: old proteins performing new tricks</article-title>. <source/>Neuron
<year>1996</year>;<volume>17</volume>:<fpage>587</fpage>–<lpage>593</lpage>.<pub-id pub-id-type="pmid">8893017</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Stumpel</surname><given-names>C</given-names></name><name><surname>Vos</surname><given-names>YJ</given-names></name></person-group>
<article-title>L1 syndrome</article-title>. In: <source/>GeneReviews [online]. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK1484/">http://www.ncbi.nlm.nih.gov/books/NBK1484/</ext-link>. Accessed May 22, 2015</comment>.</mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fransen</surname><given-names>E</given-names></name><name><surname>Van Camp</surname><given-names>G</given-names></name><name><surname>D'Hooge</surname><given-names>R</given-names></name><name><surname>Vits</surname><given-names>L</given-names></name><name><surname>Willems</surname><given-names>PJ</given-names></name></person-group>
<article-title>Genotype-phenotype correlation in L1 associated diseases</article-title>. <source/>J Med Genet
<year>1998</year>;<volume>25</volume>:<fpage>399</fpage>–<lpage>404</lpage>.<pub-id pub-id-type="pmid">9610803</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Jouet</surname><given-names>M</given-names></name><name><surname>MacFarlane</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>JS</given-names></name><name><surname>Kenwrick</surname><given-names>S</given-names></name><name><surname>Chothia</surname><given-names>C</given-names></name></person-group>
<article-title>Outline structure of the human L1 cell adhesion molecule and the sites where mutations cause neurological disorders</article-title>. <source/>EMBO J
<year>1996</year>;<volume>15</volume>:<fpage>6050</fpage>–<lpage>6059</lpage>.<pub-id pub-id-type="pmid">8947027</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Angelis</surname><given-names>E</given-names></name><name><surname>MacFarlane</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>JS</given-names></name><etal></etal></person-group>
<article-title>Pathological missense mutations of neural cell adhesion molecule L1 affect hemophilic and heterophilic binding activities</article-title>. <source/>EMBO J
<year>1999</year>;<volume>18</volume>:<fpage>4744</fpage>–<lpage>4753</lpage>.<pub-id pub-id-type="pmid">10469653</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>AJ</given-names></name><name><surname>Cho</surname><given-names>MT</given-names></name><name><surname>Millan</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Mutations in SPATA5 are associated with microcephaly, intellectual disability, seizures, and hearing loss</article-title>. <source/>Am J Hum Genet
<year>2015</year>;<volume>97</volume>:<fpage>457</fpage>–<lpage>464</lpage>.<pub-id pub-id-type="pmid">26299366</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Mort</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>EV</given-names></name><etal></etal></person-group>
<article-title>The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics</article-title>. <source/>Hum Genomics
<year>2009</year>;<volume>4</volume>:<fpage>69</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">20038494</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Kamei</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Brain development in mice lacking L1-L1 homophilic adhesion</article-title>. <source/>J Cell Biol
<year>2004</year>;<volume>165</volume>:<fpage>145</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">15067019</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Umekage</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Downregulation of L1 perturbs neuronal migration and alters the expression of transcription factors in murine neocortex</article-title>. <source/>J Neurosci Res
<year>2013</year>;<volume>91</volume>:<fpage>42</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">23073969</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tonosaki</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Umekage</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>L1CAM is crucial for cell locomotion and terminal translocation of the soma in radial migration during murine corticogensis</article-title>. <source/>PLoS One
<year>2014</year>;<volume>9</volume>:<fpage>e86186</fpage>.<pub-id pub-id-type="pmid">24489698</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>WED</given-names></name><name><surname>Born</surname><given-names>DE</given-names></name><name><surname>Sarnat</surname><given-names>HB</given-names></name></person-group>
<article-title>The pachygyria-polymicrogyria spectrum of cortical dysplasia in X-linked hydrocephalus</article-title>. <source/>Eur J Pediatr Surg
<year>1998</year>;<volume>8</volume>:<fpage>10</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">9926316</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wieck</surname><given-names>G</given-names></name><name><surname>Leventer</surname><given-names>RJ</given-names></name><name><surname>Squier</surname><given-names>WM</given-names></name><etal></etal></person-group>
<article-title>Periventricular nodule heterotopia with overlying polymicrogyria</article-title>. <source/>Brain
<year>2005</year>;<volume>128</volume>:<fpage>2811</fpage>–<lpage>2821</lpage>.<pub-id pub-id-type="pmid">16311271</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Xq26.1-26.2 gain identified on array comparative genomic hybridization in bilateral periventricular nodular heterotopia with overlying polymicrogyria</article-title>. <source/>Dev Med Child Neurol
<year>2014</year>;<volume>56</volume>:<fpage>1221</fpage>–<lpage>1224</lpage>.<pub-id pub-id-type="pmid">25052774</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>